Zhejiang Shengda Bio-Pharm Hits Day Low Amid Price Pressure, Now at CNY 15.17

Zhejiang Shengda Bio-Pharm Co., Ltd. experienced a significant decline today, with the stock dropping by 7.97% as it reached an intraday low of CNY 15.17. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.63% on the same day. Over the past week, Zhejiang Shengda has seen a more pronounced downturn, with a 19.03% decrease, while its monthly performance reflects a 22.5% drop. Despite these short-term challenges, the company has reported positive results in its last three consecutive quarters, including a notable increase in net profit, which grew by 77.05% to CNY 31.63 million. Financial metrics indicate a low return on capital employed (ROCE) of 2,670.04%, suggesting limited profitability relative to total capital. The company's market capitalization stands at CNY 1,298 million, categorizing it as a small-cap entity within the pharmaceuticals and biotechnology sector. With a price-to-earnings ratio of 56.00 and a price-to-book value of 0.82, Zhejiang Shengda continues to navigate a challenging market environment.